StockData

Protalix BioTherapeutics vs Pelthos Therapeutics

PLX and PTHS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How PLX and PTHS compare

Protalix BioTherapeutics is the larger company, worth 8.9 times as much as Pelthos Therapeutics ($244M against $27.4M).

Protalix BioTherapeutics keeps more of each dollar of sales as profit, with a net margin of 23.5% compared with −200% at Pelthos Therapeutics.

Protalix BioTherapeutics scores higher on the StockData Score (16 against 2 for Pelthos Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricPLXPTHS
Size and price
Market cap$244M$27.4M
Share price$3.03$7.15
Change, 1 year57.0%−79.4%
Change, 5 years206%–
Beta (5Y)1.330.91
Employees22692
StockData Score
Total score16 (better)2
Valuation score4 (better)1
Growth score2 (better)0
Performance score4 (better)0
Health score6 (better)1
Dividend score00
Valuation
P/E13.2×–
P/S3.0×0.6× (better)
P/B3.4×–
EV/EBITDA9.3×–
P/FCF31.8×–
FCF yield3.1%–
Fair value$5.40–
Margin of safety43.9%–
Growth
Revenue growth (TTM)30.1%–
Revenue growth, 5Y average−3.5%–
Net income growth (TTM)202%–
EPS growth (TTM)475%–
Profitability
Gross margin69.2%78.6% (better)
Operating margin28.9% (better)−133%
Net margin23.5% (better)−200%
FCF margin9.5%–
Return on equity31.2%–
Return on invested capital49.5%–
Financial health
Debt / equity0.00–
Interest coverage–−7.8×
Current ratio2.94 (better)1.98
Altman Z-score5.85 (better)−1.83
Piotroski F-score45 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions17.9%35.6%
Held by insiders3.8%–
Insider net buying, 12 months$101K$794K (better)
Short interest, % of float4.5%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.